Piper Sandler analyst David Westenberg lowered the firm’s price target on Cytek Biosciences to $15 from $18 and keeps an Overweight rating on the shares. The analyst updated the model to reflect the company’s recent earnings report.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CTKB:
- Cytek® Biosciences Introduces New 20-Color AML Panel
- Cytek Biosciences reports Q4 revenue $48.3M, consensus $50.22M
- Cytek Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results
- DiaSorin completes sale of Flow Cytometry & Imaging business to Cytek
- Sale of Flow Cytometry and Imaging Business From DiaSorin to Cytek® Biosciences Completed